NCT02096679View on ClinicalTrials.gov

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

AZD9291

Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1

Trial Locations (1)

Unknown

Research Site, Nottingham

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY